Funding Details
- Awarder
- SemiNews
- Date Award
- June 12, 2024
- Vertical
- Healthcare Technology
- Funding URL
- View Funding Page
Company Info
- Founding Year
- Not provided in the memo
- Traction
- Injectsense has provided sensors for animal testing at Johns Hopkins University's Wilmer Eye Institute and is preparing for first-in-human studies in Santiago, Chile. The company is ramping up production of prototype devices and has a board of medical advisors actively contributing to design considerations and safety aspects.
- Organizations Involved
- Johns Hopkins University, IDEC Group, Bpifrance
- Founders
- Ariel Cao
- Company Description
- Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database. Injectsense: Improved Care Through Continuous Information
Injectsense enables tracking of progressive disease indicators and improved therapy management by providing continuous, clinically actionable information through an injectable ultra-miniature sensor coupled with a secure digital health platform. Our sensor, which can be delivered during a single doctor's office visit, transforms the care model by enabling medical teams to track the disease at the pace of its evolution, whether months or years, receive early warning signs and provide preventive therapy. The configurable-on-demand sensor monitors patients 24/7, requires no patient lifestyle changes and reduces the need for medical office visits. More significantly, it allows physicians to establish an individual patient baseline for comparison, to receive data quickly at any time of day, to see histories and hourly dynamic disease state before irreversible damage is done, and to increase the effectiveness of drug therapy by tracking the effects of pharmaceuticals on key indicators over time.
- Market
- Medical Devices
- Location
-
Emeryville,
CA,
US
- Coinvestors
- Private investors, IDEC Group, Bpifrance
Links